

**Tremfya (guselkumab)**  
**Prior Authorization Request Form**  
 Caterpillar Prescription Drug Benefit  
 Phone: 877-228-7909 Fax: 800-424-7640

**MEMBER'S LAST NAME:** \_\_\_\_\_ **MEMBER'S FIRST NAME:** \_\_\_\_\_

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

**URGENT**

MEMBER INFORMATION	
<b>LAST NAME:</b>	<b>FIRST NAME:</b>
<b>PHONE NUMBER:</b>	<b>DATE OF BIRTH:</b>
<b>STREET ADDRESS:</b>	
<b>CITY:</b>	<b>STATE:                      ZIP CODE:</b>
<b>PATIENT INSURANCE ID NUMBER:</b>	

**MALE**    **FEMALE**   **HEIGHT (IN/CM):** \_\_\_\_\_   **WEIGHT (LB/KG):** \_\_\_\_\_   **ALLERGIES:** \_\_\_\_\_

**IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [PRIMETHERAPEUTICS.COM/NOPP](http://PRIMETHERAPEUTICS.COM/NOPP)**

**PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):** \_\_\_\_\_  
**AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:** \_\_\_\_\_

PRESCRIBER INFORMATION	
<b>LAST NAME:</b>	<b>FIRST NAME:</b>
<b>PRESCRIBER SPECIALTY:</b>	<b>EMAIL ADDRESS:</b>
<b>NPI NUMBER:</b>	<b>DEA NUMBER:</b>
<b>PHONE NUMBER:</b>	<b>FAX NUMBER:</b>
<b>STREET ADDRESS:</b>	
<b>CITY:</b>	<b>STATE:                      ZIP CODE:</b>
<b>REQUESTER (if different than prescriber):</b>	<b>OFFICE CONTACT PERSON:</b>

MEDICATION OR MEDICAL DISPENSING INFORMATION			
<b>MEDICATION NAME:</b>			
<b>DOSE/STRENGTH:</b>	<b>FREQUENCY:</b>	<b>LENGTH OF THERAPY/REFILLS:</b>	<b>QUANTITY:</b>
<input type="checkbox"/> <b>NEW THERAPY</b> <input type="checkbox"/> <b>RENEWAL</b>		<b>IF RENEWAL: DATE THERAPY INITIATED:</b>	
<b>DURATION OF THERAPY (SPECIFIC DATES):</b>			

*Continued on next page*



**Tremfya (guselkumab)**  
**Prior Authorization Request Form**  
 Caterpillar Prescription Drug Benefit  
 Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?		
<input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
<b>MEDICATION/THERAPY</b> (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	<b>RESPONSE/REASON FOR FAILURE/ALLERGY:</b>
2. LIST DIAGNOSES:		ICD-10:
<input type="checkbox"/> Plaque psoriasis <input type="checkbox"/> Psoriatic arthritis <input type="checkbox"/> Ulcerative colitis <input type="checkbox"/> Crohn's disease <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s):		
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
Is patient going to be using drug in combination with a clinical trial? <input type="checkbox"/> Yes <input type="checkbox"/> No		
<b><u>Initial Request:</u></b> Will the patient be using Tremfya concurrently with another biologic response modifier or immunomodulatory agent? <input type="checkbox"/> Yes <input type="checkbox"/> No		
Will patient stop use of their biologic response modifier or immunomodulatory agent when they start use with Tremfya? <input type="checkbox"/> Yes <input type="checkbox"/> No		
Has the patient had a 3-month trial and inadequate response to the Humira biosimilar adalimumab-aacf? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.		
Does patient have an absolute contraindication to the biosimilar adalimumab-aacf? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.		
Has the patient tried and had an inadequate response to a 4- month trial of the <u>biosimilar</u> for Stelara- <u>Otulfi(ustekinumb-aauz)</u> ? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.		
Does patient have a absolute contraindication to the biosimilar for <u>Stelara-Otulfi(ustekinumb-aauz)</u> ? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation.		
Has patient been previously treated with infliximab? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation with dates of service.		
Has patient been previously treated with vedolizumab? <input type="checkbox"/> Yes <input type="checkbox"/> No Please submit documentation with dates of service.		



**Tremfya (guselkunmab)**  
**Prior Authorization Request Form**  
Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

- Is Tremfya prescribed by a dermatologist?  Yes  No  
Is Tremfya prescribed by a rheumatologist?  Yes  No  
Is Tremfya prescribed by a gastroenterologist?  Yes  No

**For Plaque Psoriasis / Psoriatic Arthritis:**

Does the patient have plaques covering at least 10% of their body surface area (BSA) or less than 10% of BSA with involvement of palms, soles, head and neck, or genitalia which cause disruption of normal activities?  Yes  No

Has the patient had an inadequate response to topical therapy (e.g., corticosteroids, anthralin, calcipotriene, tazarotene)?\*  Yes  No

Select if the patient has had a trial and inadequate response to the following phototherapy options:

- Psoralens with UVA light (PUVA)
- UVB with coal tar

Has patient had a trial and failure with a three-month course of one of the following conventional disease modifying anti-rheumatic agents (DMARDs) [e.g., methotrexate, acitretin, sulfasalazine [Azulfidine®], leflunamide [Arava®] or hydroxychloroquine or cyclosporine)?  
 Yes  No *Please submit documentation.*

Does the patient have documentation of a contraindication to all conventional DMARD systemic therapies indicated for their disease?  Yes  No *\*Must provide documentation*

**For Ulcerative colitis:**

Has patient tried and failed at least one of the following three therapies: corticosteroids, azathioprine and/or 6-mercaptopurine?  Yes  No *Please provide documentation.*

Will patient use the Subcutaneous formulation of Tremfya(guselkunmab) for induction of their UC?  Yes  No *Please provide start date.*

Has patient already started their induction therapy?  Yes  No *Please provide start dates.*

Does patient only need authorization for the maintenance therapy?  Yes  No *Please provide documentation.*

**For Crohn's Disease:**

Has patient had a trial of glucocorticoid therapy or methotrexate or azathioprine or 6-mercaptopurine or 5-ASA/mesalamine?  Yes  No *Please submit documentation.*

Will patient use the Subcutaneous formulation of Tremfya(guselkunmab) for induction of their UC?  Yes  No *Please provide start date.*

Has patient already started their induction therapy?  Yes  No *Please provide start dates.*

Does patient only need authorization for the maintenance therapy?  Yes  No *Please provide documentation.*

**Tremfya (guselkumab)**  
**Prior Authorization Request Form**  
Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

**MEMBER'S LAST NAME:** \_\_\_\_\_ **MEMBER'S FIRST NAME:** \_\_\_\_\_

**Renewal Request:**

**Is prescriber a dermatologist?**  Yes  No

**Is prescriber a rheumatologist?**  Yes  No

**Is Tremfya prescribed by a gastroenterologist?**  Yes  No

**Is patient continuing to respond to therapy?**  Yes  No *Please submit documentation.*

**Will patient use requested medication in combination with another biologic response modifier or immunomodulatory agent?**  Yes  No

**Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?**

---

**Please note:** Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

**ATTESTATION:** I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Prescriber Signature or Electronic I.D. Verification:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

**FAX THIS FORM TO:** 800-424-7640  
**MAIL REQUESTS TO:** Prime Therapeutics Management Prior Authorization Program  
Attn: CP-4201  
P.O. Box 64811  
St. Paul, MN 55164-0811  
**Phone:** 877-228-7909